Several healthcare companies, including Kadant and Hims & Hers Health, reported significant market-beating returns over five years.
1 report, 0 independent
Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Several healthcare companies, including Kadant and Hims & Hers Health, reported significant market-beating returns over five years.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Kadant
US-based paper company
Nothing else this week.
-
Hims & Hers Health
American telehealth company
Nothing else this week.
-
Organon & Co.
pharmaceutical company
Nothing else this week.
-
Merck
public company in Indonesia
Related events
- Merck's stock price increased following positive drug performance involving Summit Therapeutics.
- Healthcare stocks surged to record highs on August 19, 2026, amid market excitement over drug breakthroughs involving Moderna, Amgen, and Merck.
- Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.
- Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.
- Moderna and Merck announced initial results from a late-stage trial for their novel cancer treatment.
Coverage
Newest first; wire copies grouped- Unknown outlet